N/A
Completed N=50
Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)
Source: ClinicalTrials.gov NCT00725010 ↗Enrolled (actual)
50
Serious AEs
18.0%
Results posted
Nov 2010
Primary outcomePrimary: Safety: Number of Adverse Events in the Indicated Categories — 35; 1; 14; 0 Adverse Events
Summary
The purpose of this program is to evaluate the safety, tolerability, and efficacy of the new concomitant and sequential temozolomide regimen in newly diagnosed Glioblastoma patients in a routine care setting.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Safety: Number of Adverse Events in the Indicated Categories |
35; 1; 14; 0; 22; 1 | — |
| PRIMARY Number of Participants Who Discontinued Due to Toxicity |
8; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Newly diagnosed Glioblastoma multiforme
Exclusion Criteria
- History of hypersensitivity to temozolomide or its components, or to dacarbazine.
- Women who are pregnant or breast-feeding.
- Patients with severe myelosuppression.
Data sourced from ClinicalTrials.gov (NCT00725010). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.